N-{4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide

• ChemBase ID: 155783
• Molecular Formular: C15H9F6N5OS
• Molecular Mass: 421.3202792
• Monoisotopic Mass: 421.04320025
• SMILES: Cc1c(snn1)C(=O)Nc1ccc(cc1)n1c(cc(n1)C(F)(F)F)C(F)(F)F
• Canonical SMILES: O=C(c1snnc1C)Nc1ccc(cc1)n1nc(cc1C(F)(F)F)C(F)(F)F
• InChI: InChI=1S/C15H9F6N5OS/c1-7-12(28-25-23-7)13(27)22-8-2-4-9(5-3-8)26-11(15(19,20)21)6-10(24-26)14(16,17)18/h2-6H,1H3,(H,22,27)
• InChIKey: XPRZIORDEVHURQ-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: N-{4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide
• IUPAC Traditional name: N-{4-[3,5-bis(trifluoromethyl)pyrazol-1-yl]phenyl}-4-methyl-1,2,3-thiadiazole-5-carboxamide
• Synonyms: 4-methyl-4′-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide; YM-58483

Database IDs

• CAS Number: 223499-30-7
• MDL Number: MFCD00220976
• PubChem SID: 162249921
• PubChem CID: 2455

CALCULATED PROPERTIES

• Acid pKa: 10.221489
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 4.065037
• LogD (pH = 7.4): 4.0644226
• Log P: 4.065045
• Molar Refractivity: 90.0797 cm^3
• Polarizability: 31.5034 Å^3
• Polar Surface Area: 72.7 Å^2
• Rotatable Bonds: 5
• Lipinski's Rule of Five: true

PROPERTIES

Physical Property

• Solubility: DMSO: >10 mg/mL
• Apperance: white solid

Safety Information

• European Hazard Symbols: Harmful (Xn)
• German water hazard class: 3
• Risk Statements: 22-36/37/38
• Safety Statements: 26-36/37
• GHS Pictograms: GHS07
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H315-H319-H335
• GHS Precautionary statements: P261-P305 + P351 + P338
• Personal Protective Equipment: dust mask type N95 (US), Eyeshields, Gloves
• Storage Temperature: 2-8°C

Product Information

• Purity: ≥98% (HPLC)
• Empirical Formula (Hill Notation): C15H9F6N5OS

DETAILS

Sigma Aldrich - Y4895

Biochem/physiol Actions
YM-58483 is a selective Ca++ release-activated Ca++ (CRAC) [a.k.a. store-operated Ca++ (SOC) channels] that mediate Ca++ influx in T cells and other inflammatory cells. CRAC channel inhibitors have potential clinical applications in autoimmune disease, transplant rejection, allergic airway inflammation and bronchial asthma. YM-58483 is also promoted as a tool for CRAC studies; may be used as a gold standard.